# TrialGuard AI

## Product Objective

TrialGuard AI is a clinical trial risk intelligence and data quality
platform designed to help clinical operations and statistical teams
identify emerging trial-site risks, detect unusual data patterns,
prioritize sites for investigation, and understand the factors
contributing to each risk.

The system is intended as a decision-support tool. It does not make
clinical decisions or automatically determine actions.

## Business Problem

Clinical trials generate large volumes of data across clinical sites,
patients, visits, laboratory measurements, adverse events, protocol
deviations, and operational activities.

As the number of sites and patients increases, manually reviewing every
site and identifying emerging risks becomes difficult and time-consuming.

TrialGuard AI addresses this problem by continuously analyzing
trial-site and operational data to:

1. Detect unusual data patterns.
2. Identify sites showing deteriorating performance.
3. Predict the probability of a site becoming high-risk.
4. Prioritize sites that require investigation.
5. Explain the major factors contributing to each risk score.
6. Track risk trends over time.

The objective is not to replace clinical or statistical experts.
Instead, the system provides an AI/ML-based decision-support layer
that helps experts focus their attention on the sites and patterns
that are most likely to require investigation.

## Problem Statement

How can machine learning and statistical monitoring be used to
identify emerging clinical-trial site risks early, prioritize the
most important sites for investigation, and provide transparent
explanations for why a site has been classified as high-risk?

## Target Users

### 1. Clinical Operations Team

The clinical operations team uses TrialGuard AI to identify trial
sites that may require additional investigation or monitoring.

Key needs:

- Identify high-risk sites.
- Prioritize sites requiring attention.
- Monitor changes in site performance.
- Understand the primary drivers of increasing risk.
- Review historical risk trends.

### 2. Biostatistics / Statistical Monitoring Team

The biostatistics and statistical monitoring team uses the platform
to identify unusual data patterns and support centralized statistical
monitoring.

Key needs:

- Detect atypical data patterns.
- Identify statistical anomalies.
- Compare sites against appropriate benchmarks.
- Analyze risk trends over time.
- Understand the evidence behind model predictions.
- Investigate potential data-quality signals.

### 3. Data Science / AI Team

The Data Science and AI team is responsible for the analytical and
machine-learning components of the platform.

Key needs:

- Monitor model performance.
- Evaluate prediction quality.
- Understand feature importance.
- Monitor data quality and model inputs.
- Detect potential model drift.
- Track model and pipeline health.

## User-to-Product Mapping

| User | Primary Question | TrialGuard AI Response |
|---|---|---|
| Clinical Operations | Which sites need attention? | Ranked site risk list |
| Clinical Operations | Why is this site risky? | Risk explanation |
| Biostatistics | Is this data pattern unusual? | Anomaly detection |
| Biostatistics | How has risk changed? | Temporal risk trends |
| Data Science | Is the model reliable? | Model performance monitoring |
| Data Science | What drives predictions? | Feature importance / SHAP |

## Primary Machine Learning Objective

The primary machine learning objective is to predict whether a
clinical trial site will become high-risk during the next monitoring
period.

This is formulated as a binary classification problem.

Target variable:

- `high_risk_next_period = 0`: Site does not become high-risk.
- `high_risk_next_period = 1`: Site becomes high-risk.

The model will use only information available up to the current
monitoring period to predict future site risk.

Potential predictive features include:

- Missing data rate
- Protocol deviation rate
- Patient dropout rate
- Visit delay
- Data entry delay
- Query resolution time
- Adverse event rate
- Patient enrollment rate
- Historical site performance

Future information must not be used as model input when predicting
future risk, in order to prevent data leakage.

## Machine Learning Problem Type

Primary problem:
Binary Classification

Input:
Historical site-level clinical trial and operational metrics.

Output:
Probability that the site will become high-risk in the next
monitoring period.

Example:

Site 102 → Risk probability: 0.87

Prediction:
HIGH RISK

The probability score will be used to prioritize sites for
investigation rather than automatically making clinical or
operational decisions.

## Risk Definition

TrialGuard AI will use a composite risk framework to generate the
ground-truth risk state for the synthetic clinical-trial environment.

The risk score will combine multiple independent operational and
data-quality signals:

| Risk Factor | Weight |
|---|---:|
| Missing data rate | 20% |
| Protocol deviation rate | 20% |
| Patient dropout rate | 15% |
| Visit delay | 15% |
| Data-entry delay | 10% |
| Query resolution time | 10% |
| Enrollment deterioration | 10% |

The resulting score will range from 0 to 100.

Risk categories:

- 0–39: LOW
- 40–69: MEDIUM
- 70–100: HIGH

The risk score is used to create the synthetic ground-truth state
for model development and evaluation.

The predictive model will not directly use the final risk score as
an input. Instead, it will use the underlying operational and
data-quality features to predict whether the site will become
high-risk during the next monitoring period.

## Risk Progression

Risk will be modeled dynamically over multiple monitoring periods.

Some synthetic sites will remain stable, while others will gradually
deteriorate across multiple periods.

Example:

Week 1 → Risk Score 32 → LOW
Week 2 → Risk Score 38 → LOW
Week 3 → Risk Score 47 → MEDIUM
Week 4 → Risk Score 59 → MEDIUM
Week 5 → Risk Score 73 → HIGH

This allows TrialGuard AI to identify both current high-risk sites
and emerging risk trends.

## Data Architecture

TrialGuard AI will use a relational data architecture representing
multiple aspects of a synthetic clinical trial.

### Core Entities

1. Trials
2. Sites
3. Patients
4. Visits
5. Laboratory Results
6. Adverse Events
7. Operational Events

### Entity Relationships

A trial can contain multiple clinical sites.

A site can enroll multiple patients.

A patient can have multiple visits, laboratory results, and adverse
events.

A site can also have multiple operational events such as missing
data, protocol deviations, data-entry delays, and query-resolution
events.

### Core Tables

#### trials

- trial_id
- trial_name
- therapeutic_area
- phase
- start_date
- end_date
- target_enrollment

#### sites

- site_id
- trial_id
- country
- city
- site_type
- investigator_experience
- target_patients

#### patients

- patient_id
- site_id
- enrollment_date
- age
- sex
- treatment_group
- status

#### visits

- visit_id
- patient_id
- visit_type
- scheduled_date
- actual_date
- visit_delay_days
- completed

#### lab_results

- lab_id
- patient_id
- visit_id
- test_name
- result
- reference_low
- reference_high
- abnormal_flag

#### adverse_events

- event_id
- patient_id
- site_id
- event_date
- event_type
- severity
- serious
- reported_delay_days

#### operational_events

- event_id
- site_id
- event_date
- event_type
- value

Operational event types may include:

- Missing data
- Protocol deviation
- Data-entry delay
- Query resolution

## Synthetic Dataset Scale

The initial synthetic environment will contain:

- 5 clinical trials
- Approximately 40–60 sites per trial
- Approximately 80–150 patients per site
- 12 monitoring periods per site
- Multiple visits per patient
- Multiple laboratory observations per patient
- Multiple operational events per site

The expected dataset will contain approximately 250 sites and
25,000–35,000 synthetic patients, with potentially hundreds of
thousands of visit, laboratory, adverse-event, and operational
records.

The dataset will be sufficiently large to support exploratory
analysis, statistical monitoring, anomaly detection, supervised
machine learning, and time-based model evaluation.

## Synthetic Site Behavior

The synthetic data generation process will simulate different types
of clinical-trial site behavior.

### Stable Sites

Sites with generally healthy operational performance, low missing
data, few protocol deviations, low patient dropout, and timely
data entry.

### Gradually Deteriorating Sites

Sites whose operational and data-quality metrics worsen gradually
over multiple monitoring periods.

### High-Risk Sites

Sites exhibiting consistently poor operational and data-quality
performance.

### Anomalous Sites

Sites that generally behave normally but experience sudden and
unusual changes in selected metrics.

These behavioral patterns will provide realistic variation for
developing and evaluating TrialGuard AI's risk prediction and
anomaly-detection capabilities.